Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)
Status:
Completed
Trial end date:
2016-04-20
Target enrollment:
Participant gender:
Summary
Previous studies in Western country show that triple-negative breast cancer has aggressive
clinical and pathological features compared with non-triple negative breast cancer, including
onset at a young age, advanced clinical stage, high histologic and nuclear grade and more
distant recurrence.
According to the characteristics of triple negative breast tumor, the TNBC patients can
benefit neither from hormonal therapies nor from target therapies against Her2 receptors. The
only systemic therapy currently available is chemotherapy, and prognosis remains poor. It
becomes more and more important to investigate the sensitive chemotherapy regimen for triple
negative patients.
Cisplatin-based regimen was active for the patients of lung cancer, colorectal cancer and
ect. Triple negative breast cancer patients were more sensitive to platinum-based
chemotherapy regimens according to the results of some retrospective studies.
The investigators hypothesized that paclitaxel combined with cisplatin is more sensitive to
triple negative breast cancer compared with CEF followed by docetaxel.